Equities

Immuneering Corp

IMRX:NMQ

Immuneering Corp

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)2.42
  • Today's Change0.14 / 6.14%
  • Shares traded4.12m
  • 1 Year change-69.41%
  • Beta--
Data delayed at least 15 minutes, as of Sep 19 2024 21:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of USD
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments86106149
Total Receivables, Net00.010.25
Total Inventory------
Prepaid expenses3.423.212.89
Other current assets, total------
Total current assets89109152
Property, plant & equipment, net5.405.786.13
Goodwill, net6.696.696.70
Intangibles, net0.380.410.44
Long term investments--01.00
Note receivable - long term------
Other long term assets1.030.740.10
Total assets103122167
LIABILITIES
Accounts payable2.113.151.39
Accrued expenses5.474.884.24
Notes payable/short-term debt000
Current portion long-term debt/capital leases------
Other current liabilities, total0.260.02--
Total current liabilities7.858.055.63
Total long term debt000
Total debt000
Deferred income tax------
Minority interest------
Other liabilities, total4.164.465.09
Total liabilities121311
SHAREHOLDERS EQUITY
Common stock0.030.030.03
Additional paid-in capital254220215
Retained earnings (accumulated deficit)(163)(110)(59)
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total0.00(0.03)(0.05)
Total equity91110156
Total liabilities & shareholders' equity103122167
Total common shares outstanding292626
Treasury shares - common primary issue----0
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.